What happened
PepGen Inc. (NASDAQ:PEPG) Chief Executive Officer James G. McArthur executed sales of 5,275 shares of the company's common stock on March 4, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The trades were completed at prices that ranged from $6.23 to $6.325 per share, producing aggregate proceeds of $32875.
Context and immediate market movement
Following the share disposals, the stock has moved lower to $5.69, a decline of roughly 9% relative to the CEO's sale prices. Short-term market data from InvestingPro cited in the filing shows an 8.6% drop in the past week, even as the company has returned approximately 147% over the previous 12 months.
Ownership after the transactions
After these sales, McArthur directly holds 296,326 shares of PepGen common stock.
Why the shares were sold
The Form 4 notes that the disposition was undertaken to satisfy minimum statutory tax withholding obligations triggered by the vesting and settlement of restricted stock units. The filing does not indicate any additional reasons for the transactions.
Recent corporate results and regulatory developments
PepGen reported a fourth-quarter loss of $0.27 per share, ahead of analyst expectations for a $0.37 loss. Despite the earnings beat, the company’s stock experienced downward pressure tied to investor concern over a partial clinical hold imposed by the U.S. Food and Drug Administration on the FREEDOM2 study.
The FREEDOM2 study, focused on DM1 MAD, remains active and continues dose escalation in the United Kingdom, Canada, and other regions. The partial hold in the United States has been linked by the company to preclinical mouse data that were submitted to the FDA in mid-2024.
Analyst stance and valuation commentary
Analysts covering PepGen maintain bullish price targets that span from $7 to $20 per share. Stifel has reiterated a Buy rating with a $12.00 price target. Separately, InvestingPro’s analysis is cited as indicating that the stock currently trades above its Fair Value estimate.
Note
The Form 4 filing and the company’s public disclosures supply the factual basis for this report. Where details are limited in those filings, this article reflects the available information without additional inference.